FDA
CBD Oil Still Under Attack
Editor’s Note: This article is intended for information purposes only. Because state and municipal laws vary greatly, as do the circumstances of individual cases,...
Transparency Wins the Day
By Dagan Xavier, Co-Founder & Senior Vice President of Data at Label Insight
On May 20, 2016, the FDA announced a new, improved Nutrition Facts...
FDA Officially Extends Nutrition Facts Label Compliance Date
Washington, D.C. - Food manufacturers have received an 18-month extension for meeting updated nutrition and serving size requirements on product labels.
The U.S. Food and Drug...
FDA Panel Votes To Approve Epilepsy Medication Made with CBD Oil
Washington, D.C. - A Food and Drug Administration advisory panel yesterday unanimously recommended approval of an epilepsy medication made with CBD oil.
If the agency...
Industry Applauds FDA’s Action Against Highly Concentrated Caffeine
Washington, D.C. - Industry leaders are reacting positively to the Food and Drug Administration’s (FDA) recently published guidance about the dangers of selling bulk...
FDA Study Reveals Presence of Pharmaceutical Drugs in Some Supplements
Washington, D.C. — A U.S. Food and Drug Administration (FDA) pilot study using portable screening devices has revealed the presence of pharmaceutical drugs in...
FDA Wants to Define What’s Natural and Healthy
Washington, DC — Food and Drug Administration Commissioner Scott Gottlieb says the agency is closer to issuing guidance on the the word "natural" and...
Now We Know Vitamin D Reduces Risk of Preterm Birth, What Next?
The Organic & Natural Health Association (@OrgNatHealth) is committed to research, especially when it’s designed to demonstrate how the supplements we take favorably impact...
New Analysis Supports Health Claims for Soy Protein and Heart Disease
Washington, D.C. - The Natural Products Association (NPA) this week provided the Food and Drug Administration (FDA) with details supporting health claims that soy protein...
Public Comment Period on FDA’s Homeopathy Ruling Extended for 60 Days
The Food and Drug Administration (FDA) has extended the public comment period for its Draft Guidance ruling on homeopathic drugs for 60 days, bringing...
